MedTrace Logo

Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension

NCT03847350 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3250

Last updated 2019-02-20

No results posted yet for this study

Summary

The purpose of this study is:

To evaluate the effects of NEBILET®(Nebivolol), used as monotherapy or in combination with other antihypertensive agents, in the control of BP and in the metabolic profile of patients with essential hypertension (with or without co-morbidities) after 12 weeks and 24 weeks.

Conditions

  • Essential Hypertension

Sponsors & Collaborators

  • A.Menarini Asia-Pacific Holdings Pte Ltd

    lead INDUSTRY

Principal Investigators

  • Dae-Hyeok Kim · Inha University Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2017-03-23
Completion
2017-03-23

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03847350 on ClinicalTrials.gov